Evidence mapPaperPMID 29443207Full record

ArticleNeurology. Clinical practice2015

Alzheimer disease prevention: New optimism.

Christopher M Filley

Open access · bronzeAbstract read
In one paragraph

Article in Neurology. Clinical practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. White matter dementia then… and now.Frontiers in neurology · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Christopher M FilleyDepartments of Neurology and Psychiatry, and Behavioral Neurology Section, University of Colorado School of Medicine, Aurora, CO, and the Denver Veterans Affairs Medical Center.
Denver VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer disease (AD) poses a major threat to medicine and society, but recent epidemiologic data indicate declining incidence of the disease. This development may be due to prevention of many cases by attention to modifiable risk factors. Meanwhile, all treatment efforts using drugs targeting amyloid have failed. In contrast to the assumption of recent decades that sporadic AD is primarily a genetic disease in which neuritic plaques and neurofibrillary tangles are mainly responsible for clinical features, it is now time for a more nuanced approach that considers the role of environmental factors preceding dementia onset and the appearance of aggregated proteins. This view of AD has important implications for medical care and health policy, and for counseling individuals to adopt lifestyle strategies that can be effective for prevention.

Identifiers

PMID29443207
PMCPMC5764462
OpenAlexW2234772896

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.